Despite the group’s big losses since May, the results show Small/Micro Cap Biotechs are still richly valued. As market volatility heats up, this group faces additional downside risk.
Sep
09
2015
Small/Micro Cap Biotechnology: Still Richly Valued
Login
For full access, please enter your credentials.
Not a Subscriber?
If you are interested in subscribing to The Leuthold Group, contact us online or give us a call at 612-332-1567.
Contact UsAbout The Author
current issue
featured articles
recent tags
Equity Duration
(1)
Japan
(46)
10-Year Bond Yield
(4)
Select Industries
(176)
Risk Aversion Index
(115)
U.S. Dollar
(90)
Breadth
(106)
NYSE Advance/Decline
(20)
Gold
(82)
Real Interest Rates
(15)
Silver
(4)
S&P 500 Advances
(1)
Non-Recessionary Bottoms
(1)
VLT Signals
(25)
Market Bottoms
(2)
Russell 2000
(56)
Major Advances
(2)
S&P 500 Declines
(2)
Bear Market Rally
(23)
GDP
(45)